Written by: Bryan J. Brinda, PharmD
Download Here

This PQI will discuss proper patient selection and management of adverse events related to the administration of oral gilteritinib pharmacotherapy in patients with relapsed/refractory AML that have an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. Optimal patient identification, dosing, and follow-up are essential to help patients benefit fully while taking this medication. Continue reading Gilteritinib (XOSPATA) for Relapsed/Refractory Acute Myeloid Leukemia (AML)

Read More

Written by: Andrea Clarke, PharmD and Becky Fahrenbruch, PharmD, BCOP
Download Here

Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect that can occur with chemotherapeutics, including certain oral chemotherapy agents. Appropriate patient education and monitoring may assist with identifying early signs of peripheral neuropathy, but no agents have demonstrated efficacy in preventing CIPN. When patients experience chronic peripheral neuropathy not relieved by dose reductions or interruptions, further treatment may be warranted. Currently, the strongest evidence supports the use of duloxetine as treatment for CIPN. Other agents have demonstrated mixed results but may be useful for individual patients.
Continue reading Oral Chemotherapy-Induced Peripheral Neuropathy

Read More

Although antineoplastics have retained position as a protected class of medicines with open formularies, CMS did agree to implement Step Therapy with Medicare B medications.  And despite receiving over 4000 comments regarding price concessions and DIR fees, the agency has decided to not include a proposal to pass on price concessions negotiated by the pharmacy to patients in 2020.  These actions may limit patient access to medications and fail to address the high costs they often pay at the pharmacy counter.  Read more

Read More
image-title

MISSION STATEMENT/PHILOSOPHY:

We at Virginia Cancer Institute are dedicated to the delivery of the highest quality medical care to our patients. We are committed to treating our patients with the utmost respect and compassion. We will strive to conduct our practice in a manner in which all employees and outside healthcare providers are treated with respect for their individual contributions towards the care and wellbeing of our patients and the success in meeting the goals of our practice.

 

LOCATION(S):

Richmond, VA (5 locations)

Petersburg, VA (2 locations)

 

PRACTICE DETAILS:

300 employees

24 physicians

4 NPs/PAs

 

QUALIFICATIONS/CREDENTIALS:

QOPI Certification

 

INTRODUCTION TO PHARMACY SERVICES STAFF:

Within our oral pharmacy we have 1 Pharmacist and 2 Pharmacy Technicians. Our monthly volume of dispensed items is about 1,000.

 

DISPENSING TYPE:

Retail pharmacy

 

SERVICES PROVIDED:

Molecular Laboratory

Radiology (CT Scanning & DEXA)

IV Pharmacy

Oral Pharmacy

Chemotherapy suite

Social Worker

Dietician

Palliative Care

Blood Transfusions

Bone Marrow

 

WHY DID YOU JOIN NCODA?

To learn more about the oral oncology pharmacy industry.

 

HOW DID YOU BECOME A MEMBER?

Online via the NCODA website (www.ncoda.org).

 

HOW DID YOU HEAR ABOUT US?

We heard about NCODA through a colleague.

 

HOW CAN NCODA HELP YOU?

 To learn more about the changing market of an oral oncology pharmacy.

 

HOW WOULD YOU LIKE TO BE MORE INVOLVED WITH NCODA?

We would love to learn more about NCODA’s offerings (i.e. PQI, OCE, etc.) 

 

WHAT ARE SOME CHALLENGES YOU FACE NOW OR WILL FACE IN THE FUTURE OF ONCOLOGY?

Reimbursement and payor rules with respect to the oral oncology pharmacy.

Read More